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interactions and strategic relationships between the 
societies. The MoU will facilitate collaboration across the 
ocean on e.g. Joint Task Groups, Scientific meetings and 
Education. The development of reports (e.g. AAPM task group 
reports, professional guidelines, etc.) should seek 
collaboration between the two societies where appropriate 
and feasible. Such collaboration could be achieved by inviting 
joint membership on appropriate drafting task groups by the 
initiating society. Both societies have now Standard 
Operating Procedures (SOP) available for development of 
guidelines, which gives a good structure for initiating 
international guidelines and securing high quality reviews - 
representing both Europe and North America – in upcoming 
guidelines. 
 
Proffered Papers: Radiobiology 5: Imaging and molecular 
biomarkers in radiation oncology  
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Purpose or Objective: There is increasing evidence that 
antibodies blocking the PD-1 checkpoint (either anti-PD-1 or 
anti-PD-L1) dramatically increase in-field anti-tumor 
responses to ionizing radiation and enhance abscopal effects 
on non-irradiated metastases. Here, we developed PET 
tracers based on therapeutic surrogate antibodies that 
enable to non-invasively visualize not only the PD-1 and PD-
L1 expression in mice but also the biodistribution of the 
surrogate checkpoint-blocking antibodies. 
 
Material and Methods: Two novel PET tracers were 
developed by conjugation of anti-murine PD-1 and PD-L1 
surrogate checkpoint-blocking antibodies with the chelator 
NOTA and labeling with the radioisotope 64Cu. Non-invasive 
PET imaging was performed on naïve and tumor-bearing 
mice. Mice bearing s.c. B16 melanomas were treated with 
hypofractionated radiation therapy (hRT) using two fractions 
of 12 Gy in combination with CTLA-4 checkpoint blockade 
several days before PET imaging. PD-1 or PD-L1 knockout 
mice and PD-L1-deficient B16 cells generated using the 
CRISPR/Cas technology served as specificity controls. 
 
Results: The newly developed PD-1 and PD-L1 PET tracers 
allowed the highly specific and high-resolution imaging of PD-
1 and PD-L1 expression and of the biodistribution of the two 
therapeutic antibodies in both naïve and tumor-bearing mice 
treated with hRT and CTLA-4 checkpoint blockade. Imaging 
of the respective knockout mice, blocking experiments with 
an excess amount of unlabeled antibodies, and the analysis of 
animals bearing both wild-type B16 melanomas and PD-L1-
CRISPR knockout melanomas demonstrated the high 
specificity of the two newly developed PET tracers. The in 
vivo imaging data were confirmed by ex vivo biodistribution 
analyses. The targets of the PET tracer antibodies were 
verified by ex vivo flow cytometric analyses of tumor single-
cell suspensions and cell suspensions of secondary lymphoid 
and other organs. Interestingly, visualization of immune-
related adverse events was also possible. 
 
Conclusion: We developed two innovative PET tracers that 
allow imaging the expression of the receptor/ligand pair of 
the important PD-1 checkpoint and the biodistribution of 
surrogate checkpoint-blocking antibodies in fully 
immunocompetent mice. This technology also enabled whole-
body pictures of combination radio/immunotherapies. 
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Purpose or Objective: Objectives: Aerobic glycolysis is the 
main pathway of energy production in tumors (Warburg 
effect), and ionizing radiation is reported to switch this to 
mitochondrial oxidative phosphorylation. We developed a 
novel PET probe,18F-2-tert-butyl-4-chloro-5- {6-[2-(2-fluoro-
ethoxy)-ethoxy]-pyridin-3-ylmethoxy}-2H-pyridazin-3-one 
(18F-BCPP-EF), for imaging mitochondrial complex I (MC-I) 
activity. In this study, early detection of tumor 
radiotherapeutic effect was evaluated using 18F-BCPP-EF and 
compared with 18F-FDG and apoptosis index. 
 
Material and Methods: Methods: Tumor uptake of 18F-BCPP-
EF or 18F-FDG was examined in C3H/HeN mice inoculated 
with murine squamous cell carcinoma SCCVII after a single 
dose of x-ray irradiation, 0, 6, 15, or 30 Gy. Apoptosis 
incidence was determined by TUNEL staining in excised tumor 
tissue. 
 
Results: Results: Tumor growth suppression was dose-
dependent; tumor grew 10 fold (0 Gy), 5 fold (6 Gy), 2 fold 
(15 Gy), and reduced to half in its volume (30 Gy) 14 days 
after treatment. 18F-BCPP-EF uptake was significantly 
increased as early as 2 days (15 Gy) or 3 days (30 Gy) after 
irradiation, at time points when tumor size or apoptosis index 
showed no difference among radiation doses. In contrast, 
18F-FDG uptake was initially increased dose-dependently, 
remained elevated, and eventually decreased 10 days after 
30 Gy when tumor size was already reduced. Apoptosis index 
was increased after irradiation but failed to correlate with 
tumor response. The uptakes of 18F-BCPP-EF and 18F-FDG, as 
well as AI, were plotted against Tvol on day 14 as surrogate 
of radiotherapeutic effect. Highly significant negative 
correlations were observed between the uptake of 18F-BCPP-
EF and Tvol on day 14, as early as on day 2, and on each day 
up to day 7, and in all days combined. In contrast, between 
tumor uptake of 18F-FDG and Tvol on day 14, there was a 
significant negative correlation on day 2 and positive 
correlations on day 10 and on day 14, with no correlation in 
all days combined. 
 
Conclusion: Conclusion: Tumor uptake of 18F-BCPP-EF was 
increased dose-dependently early after irradiation when 18F-
FDG uptake and apoptosis index remained elevated 
regardless of radiation doses or its efficacy. The results 
suggest that 18F-BCPP-EF is a promising “positive” MC-I 
imaging PET probe for early detection of adequacy of tumor 
radiotherapy.  
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Purpose or Objective: PET imaging studies with the hypoxia 
tracer 18F-MISO typically show a heterogeneous distribution 
within the tumour, and regions of high uptake have been 
proposed as targets for dose painting. However, there is no 
widely-accepted method to determine dose prescriptions 
from hypoxia imaging. Oxygen diffusion distances in tissue 
(~100 μm) are smaller than the PET resolution (~4 mm) so a 
range of radiosensitivities may exist within each voxel. 
Furthermore, the perfused vasculature is not constant over 
